Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 187.80
Bid: 187.20
Ask: 189.20
Change: 0.00 (0.00%)
Spread: 2.00 (1.068%)
Open: 190.00
High: 190.00
Low: 187.80
Prev. Close: 187.80
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - PureTech Health plc

11 Oct 2022 10:03

RNS Number : 4867C
JPMorgan Securities Plc
11 October 2022
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

J.P. Morgan Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

PureTech Health plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Financial advisor to Nektar Therapeutics, Inc.

(d) Date dealing undertaken:

10 October 2022

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

Yes, Nektar Therapeutics, Inc.

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

1p ordinary

Purchase

 

Sale

205,565

 

67,176

2.2850 GBP

 

2.2850 GBP

2.2150 GBP

 

2.2200 GBP

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

1p ordinary

Equity Swap

Decrease Long

 

 

 

 

 

Decrease Short

 

Increase Long

 

 

 

 

 

Increase Short

3

1

90

269

150,961

 

5,362

 

22,000

4,000

4,000

3,000

9,702

 

9,365

2.2208 GBP

2.2450 GBP

2.2594 GBP

2.2610 GBP

2.2850 GBP

 

2.2850 GBP

 

2.2287 GBP

2.2487 GBP

2.2488 GBP

2.2501 GBP

2.2502 GBP

 

2.2431 GBP

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

Date of disclosure:

11 October 2022

Contact name:

Alwyn Basch

Telephone number:

020 7742 7407

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERKFLBFLBLBFBL
Date   Source Headline
4th Oct 20194:35 pmRNSPrice Monitoring Extension
4th Oct 201912:07 pmRNSSecond Price Monitoring Extn
4th Oct 201912:02 pmRNSPrice Monitoring Extension
2nd Oct 20197:00 amRNSMinority Stake Acquisition & PDMR Notification
1st Oct 20194:40 pmRNSSecond Price Monitoring Extn
1st Oct 20194:35 pmRNSPrice Monitoring Extension
1st Oct 20191:15 pmRNSVor Appoints Senior Cell & Gene Therapy Leaders
1st Oct 20197:00 amRNSTotal Voting Rights
23rd Sep 20194:40 pmRNSSecond Price Monitoring Extn
23rd Sep 20194:35 pmRNSPrice Monitoring Extension
23rd Sep 201912:07 pmRNSSecond Price Monitoring Extn
23rd Sep 201912:02 pmRNSPrice Monitoring Extension
23rd Sep 20197:00 amRNSVedanta Expands Series C with $62.1M Total Raised
16th Sep 20194:40 pmRNSSecond Price Monitoring Extn
16th Sep 20194:35 pmRNSPrice Monitoring Extension
9th Sep 201912:07 pmRNSSecond Price Monitoring Extn
9th Sep 201912:02 pmRNSPrice Monitoring Extension
9th Sep 20197:00 amRNSPureTech Announces Board Change
6th Sep 20194:41 pmRNSSecond Price Monitoring Extn
6th Sep 20194:35 pmRNSPrice Monitoring Extension
4th Sep 201912:07 pmRNSSecond Price Monitoring Extn
4th Sep 201912:02 pmRNSPrice Monitoring Extension
27th Aug 20197:00 amRNSPureTech Health plc Half-Year Report
20th Aug 20197:00 amRNSNotice of Results
19th Aug 201912:02 pmRNSPrice Monitoring Extension
14th Aug 20195:30 pmRNSBTG
7th Aug 20191:40 pmRNSVor Names Biotech Vet Robert Ang President & CEO
1st Aug 20197:00 amRNSTotal Voting Rights
31st Jul 20191:40 pmRNSVor Biopharma Adds R&D Leader Bill Lundberg to BOD
17th Jul 20197:00 amRNSPRTC Acquires Clinical Stage Asset for Lymphedema
11th Jul 20197:00 amRNSPotential US Listing of PureTech Health on Nasdaq
9th Jul 20197:00 amRNSPRTC Immuno-Oncology Programme Granted US Patent
3rd Jul 20197:00 amRNSPRTC's Karuna closes IPO, gross proceeds $102.6M
1st Jul 20197:00 amRNSFirst Patient in Vedanta Food Allergy Study
28th Jun 20197:00 amRNSPureTech's Karuna successfully lists on NASDAQ
20th Jun 20197:00 amRNSPureTech Announces New Corporate HQ/Internal Labs
13th Jun 20197:00 amRNSFollica Positive Interim Data & Plans for Pivotal
3rd Jun 20197:00 amRNSPRTC's Karuna Files Public S1 for NASDAQ IPO
30th May 20197:05 amRNSPRTC to Present at Jefferies US Conference
30th May 20197:00 amRNSResult of AGM
29th May 20197:00 amRNSVor Publishes POC Study in Scientific Journal
21st May 20197:00 amRNSVedanta Presents Expanded Data from Successful Ph1
20th May 20197:00 amRNSPromising Gelesis Data in Chronic Constipation
14th May 20197:00 amRNSGelesis & Vedanta Data at Digestive Disease Week
13th May 20197:00 amRNSVedanta Grows Series C Financing to $45.5 Million
7th May 20197:00 amRNSVedanta Prevails in Important EU Patent Opposition
26th Apr 20197:15 amRNSPRTC's Karuna Files IPO Registration Statement
25th Apr 20197:00 amRNSGelesis Gets $10.6M Grant to Support Manufacturing
24th Apr 20197:00 amRNSFinal Results
17th Apr 20197:00 amRNSBoehringer Ingelheim & PRTC Immuno-oncology Collab

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.